These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 15314253)

  • 1. Progress toward identification of protease activity involved in proteolysis of apolipoprotein e in human brain.
    Marques MA; Owens PA; Crutcher KA
    J Mol Neurosci; 2004; 24(1):73-80. PubMed ID: 15314253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein E-related neurotoxicity as a therapeutic target for Alzheimer's disease.
    Marques MA; Crutcher KA
    J Mol Neurosci; 2003; 20(3):327-37. PubMed ID: 14501016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cathepsin D-mediated proteolysis of apolipoprotein E: possible role in Alzheimer's disease.
    Zhou W; Scott SA; Shelton SB; Crutcher KA
    Neuroscience; 2006 Dec; 143(3):689-701. PubMed ID: 16997486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of apolipoprotein E in Alzheimer's disease and its significance].
    He SR; Liu DG; Wang S; Xia YJ
    Zhonghua Bing Li Xue Za Zhi; 2005 Sep; 34(9):556-60. PubMed ID: 16468304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the Role of ApoE Fragments in Alzheimer's Disease.
    Muñoz SS; Garner B; Ooi L
    Neurochem Res; 2019 Jun; 44(6):1297-1305. PubMed ID: 30225748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragmentation of brain apolipoprotein E (ApoE) and its relevance in Alzheimer's disease.
    Amponsah AE; Feng B; Guo R; Zhang W; He J; Kong D; Dong T; Ma J; Cui H
    Rev Neurosci; 2020 Aug; 31(6):589-603. PubMed ID: 32364519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein E is a prime suspect, not just an accomplice, in Alzheimer's disease.
    Crutcher KA
    J Mol Neurosci; 2004; 23(3):181-8. PubMed ID: 15181246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOE, vascular pathology, and the AD brain.
    Yip AG; McKee AC; Green RC; Wells J; Young H; Cupples LA; Farrer LA
    Neurology; 2005 Jul; 65(2):259-65. PubMed ID: 16043796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein E interaction with the neurofibrillary tangles and senile plaques in Alzheimer disease: implications for disease pathogenesis.
    Richey PL; Siedlak SL; Smith MA; Perry G
    Biochem Biophys Res Commun; 1995 Mar; 208(2):657-63. PubMed ID: 7695621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients.
    Montine TJ; Markesbery WR; Zackert W; Sanchez SC; Roberts LJ; Morrow JD
    Am J Pathol; 1999 Sep; 155(3):863-8. PubMed ID: 10487843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease.
    Holtzman DM; Bales KR; Tenkova T; Fagan AM; Parsadanian M; Sartorius LJ; Mackey B; Olney J; McKeel D; Wozniak D; Paul SM
    Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2892-7. PubMed ID: 10694577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Apolipoprotein E4 and late-onset Alzheimer's disease].
    Tamaoka A
    Nihon Rinsho; 1994 Dec; 52(12):3257-65. PubMed ID: 7853720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ApoE genotype accounts for the vast majority of AD risk and AD pathology.
    Raber J; Huang Y; Ashford JW
    Neurobiol Aging; 2004; 25(5):641-50. PubMed ID: 15172743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoform-specific proteolysis of apolipoprotein-E in the brain.
    Elliott DA; Tsoi K; Holinkova S; Chan SL; Kim WS; Halliday GM; Rye KA; Garner B
    Neurobiol Aging; 2011 Feb; 32(2):257-71. PubMed ID: 19278755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease.
    Aleshkov S; Abraham CR; Zannis VI
    Biochemistry; 1997 Aug; 36(34):10571-80. PubMed ID: 9265639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Astrogliosis and the ApoE genotype. an immunohistochemical study of postmortem human brain tissue.
    Overmyer M; Helisalmi S; Soininen H; Laakso M; Riekkinen P; Alafuzoff I
    Dement Geriatr Cogn Disord; 1999; 10(4):252-7. PubMed ID: 10364641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An apolipoprotein E-based therapeutic improves outcome and reduces Alzheimer's disease pathology following closed head injury: evidence of pharmacogenomic interaction.
    Wang H; Durham L; Dawson H; Song P; Warner DS; Sullivan PM; Vitek MP; Laskowitz DT
    Neuroscience; 2007 Feb; 144(4):1324-33. PubMed ID: 17187933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using human induced pluripotent stem cells (hiPSCs) to investigate the mechanisms by which Apolipoprotein E (APOE) contributes to Alzheimer's disease (AD) risk.
    Raman S; Brookhouser N; Brafman DA
    Neurobiol Dis; 2020 May; 138():104788. PubMed ID: 32032733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of apolipoprotein E genotype on expression of an autosomal dominant schizophreniform disorder with progressive dementia and neurofibrillary tangles.
    Tsuang D; Raskind MA; Leverenz J; Peskind ER; Schellenberg G; Bird TD
    Biol Psychiatry; 1997 Jan; 41(2):191-5. PubMed ID: 9018389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model.
    Holtzman DM; Fagan AM; Mackey B; Tenkova T; Sartorius L; Paul SM; Bales K; Ashe KH; Irizarry MC; Hyman BT
    Ann Neurol; 2000 Jun; 47(6):739-47. PubMed ID: 10852539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.